Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, the company's subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”) received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registration of drugs produced domestically produced in GenSci 155 injection was approved. The drug is intended to prevent bronchopulmonary dysplasia (BPD) and treat primary insulin-like growth factor-1 deficiency (PIGFD) in premature infants. The route of administration is subcutaneous injection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.